Medicare Enrolled
Dr. Fazal Bari, M.D.
Hematology · Mountain Lakes, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bari from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bari?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bari
Dr. Fazal Bari is a hematology specialist in Mountain Lakes, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Bari performed 56,223 Medicare services across 2,194 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bari received a total of $13,021 from 78 pharmaceutical and/or device companies across 878 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bari is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 9% volume in NJ
$13,021 industry payments
Medicare Practice Summary
Medicare Utilization ↗56,223
Medicare services
Top 9% in NJ for hematology
2,194
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,959 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 22,400 | $43 | $90 |
| Iron infusion (Monoferric) | 11,200 | $16 | $50 |
| Denosumab injection (Prolia/Xgeva) | 5,580 | $19 | $40 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,820 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,920 | $1 | $15 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,900 | $6 | $25 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,783 | $107 | $225 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,686 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,633 | $8 | $40 |
| Flow cytometry, additional marker An additional marker is tested during a flow cytometry procedure to analyze DNA or cells. This step adds specific data points to the initial analysis. |
529 | $23 | $100 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
455 | $12 | $50 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
367 | $120 | $350 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
314 | $14 | $75 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
309 | $26 | $125 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
212 | $1 | $10 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
179 | $58 | $200 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
145 | $103 | $175 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
141 | $1 | $2 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
133 | $65 | $125 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
94 | $43 | $75 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
83 | $48 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
74 | $60 | $200 |
| New patient office visit, complex (60-74 min) | 55 | $185 | $500 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
50 | $79 | $153 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
43 | $154 | $300 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
41 | $71 | $200 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
31 | $150 | $275 |
| Flow cytometry DNA or cell analysis, first marker A laboratory test that uses a laser to analyze cells or DNA by detecting a specific marker on the cell surface or within the cell. |
25 | $71 | $200 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
21 | $24 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.6% high complexity
67.4% medium
11.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,021
Total received (2018-2024)
Avg $1,860/year across 7 years
Top 40% in NJ for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
78
Companies
878
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,515 (96.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$506 (3.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,449
2023
$1,417
2022
$1,462
2021
$1,501
2020
$1,657
2019
$2,658
2018
$2,876
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$236
Daiichi Sankyo Inc.
$128
GlaxoSmithKline, LLC.
$128
Ferring Pharmaceuticals Inc.
$109
Novartis Pharmaceuticals Corporation
$81
Janssen Biotech, Inc.
$80
Merck Sharp & Dohme LLC
$75
Mirati Therapeutics, Inc.
$64
Karyopharm Therapeutics Inc.
$54
E.R. Squibb & Sons, L.L.C.
$51
PFIZER INC.
$39
Bayer Healthcare Pharmaceuticals Inc.
$38
Blueprint Medicines Corporation
$37
Incyte Corporation
$37
ABBVIE INC.
$36
TAIHO ONCOLOGY, INC.
$23
Celltrion USA Inc.
$19
Kyowa Kirin, Inc.
$19
Eisai Inc.
$18
Myriad Genetic Laboratories, Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$17
EMD Serono, Inc.
$17
Celgene Corporation
$17
PUMA BIOTECHNOLOGY, INC.
$17
Genentech USA, Inc.
$17
Amgen Inc.
$17
PharmaEssentia USA Corporation
$16
Pharmacosmos Therapeutics Inc.
$16
Regeneron Healthcare Solutions, Inc.
$14
Aveo Pharmaceuticals, Inc.
$13
Top 3 companies account for 34.0% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,280
AstraZeneca Pharmaceuticals LP
$1,164
E.R. Squibb & Sons, L.L.C.
$1,111
Amgen Inc.
$1,054
Novartis Pharmaceuticals Corporation
$824
Merck Sharp & Dohme Corporation
$536
Incyte Corporation
$475
Daiichi Sankyo Inc.
$432
GlaxoSmithKline, LLC.
$354
Karyopharm Therapeutics Inc.
$338
Genentech USA, Inc.
$317
Seagen Inc.
$272
GENZYME CORPORATION
$271
Astellas Pharma US Inc
$262
PFIZER INC.
$244
Pharmacyclics LLC, An AbbVie Company
$234
Merck Sharp & Dohme LLC
$200
Seattle Genetics, Inc.
$195
Regeneron Healthcare Solutions, Inc.
$188
Cardinal Health 108, LLC
$174
Mirati Therapeutics, Inc.
$161
Gilead Sciences, Inc.
$148
Takeda Pharmaceuticals U.S.A., Inc.
$140
Lilly USA, LLC
$128
Myriad Genetic Laboratories, Inc.
$126
AMAG Pharmaceuticals, Inc.
$125
Blueprint Medicines Corporation
$112
Ferring Pharmaceuticals Inc.
$109
AbbVie, Inc.
$107
Eisai Inc.
$106
Celgene Corporation
$100
Kyowa Kirin, Inc.
$93
Foundation Medicine, Inc.
$87
AbbVie Inc.
$85
CTI BioPharma Corp.
$72
Bayer HealthCare Pharmaceuticals Inc.
$70
Janssen Pharmaceuticals, Inc
$69
Boehringer Ingelheim Pharmaceuticals, Inc.
$67
SANOFI-AVENTIS U.S. LLC
$60
Epizyme, Inc.,
$57
BeiGene USA, Inc.
$56
Puma Biotechnology, Inc.
$52
Verastem, Inc.
$51
Spectrum Pharmaceuticals Inc.
$47
Pharmacosmos Therapeutics Inc.
$45
Servier Pharmaceuticals LLC
$43
EISAI INC.
$42
Myovant Sciences Inc.
$40
AVEO Pharmaceuticals, Inc.
$38
Bayer Healthcare Pharmaceuticals Inc.
$38
TOLMAR Pharmaceuticals, Inc.
$37
ABBVIE INC.
$36
TESARO, Inc.
$34
EMD Serono, Inc.
$32
PharmaEssentia USA Corporation
$32
Jazz Pharmaceuticals Inc.
$31
Clovis Oncology, Inc.
$30
Alexion Pharmaceuticals, Inc.
$30
ARRAY BIOPHARMA INC
$29
Aveo Pharmaceuticals, Inc.
$29
Rigel Pharmaceuticals, Inc.
$28
Heron Therapeutics, Inc.
$26
Kite Pharma, Inc.
$25
TAIHO ONCOLOGY, INC.
$23
Celltrion USA Inc.
$19
PUMA BIOTECHNOLOGY, INC.
$17
MorphoSys, US Inc.
$16
Partner Therapeutics, Inc.
$15
ImmunoGen, Inc.
$15
TG THERAPEUTICS, INC.
$15
Acceleron Pharma, Inc.
$15
TerSera Therapeutics LLC
$14
Agios Pharmaceuticals, Inc.
$14
Sumitomo Pharma America, Inc.
$14
Horizon Therapeutics plc
$14
Pharmacyclics LLC, an AbbVie Company
$14
Ipsen Biopharmaceuticals, Inc
$12
EUSA Pharma (US) LLC
$10
Top 3 companies account for 27.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Aliqopa · Aranesp · Avastin · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · CERDELGA · CYRAMZA · Copiktra · DARZALEX · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · EVENITY · Elahere · Enhertu · Erivedge · Erleada · FARESTON · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Leukine · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Perjeta · Polivy · Poteligeo · PreciseTumor · Prolia · REBLOZYL · REBYOTA · ROLVEDON · RYDAPT · Reblozyl · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Stivarga · Sustol · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Trodelvy · UKONIQ · ULTOMIRIS · VEGZELMA · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · WELIREG · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Yescarta · ZEJULA · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematologists within 10 mi
36
Per 100K population
7.1
County median income
$134,929
Nearest hospital
SAINT CLARE'S HOSPITAL/ DENVILLE CAMPUS
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bari is a mixed practice specialist, with above-average Medicare volume (top 9% in NJ), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bari experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Bari performed 22,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bari receive payments from pharmaceutical companies?
Yes. Dr. Bari received a total of $13,021 from 78 companies across 878 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bari's costs compare to other hematologists in Mountain Lakes?
Dr. Bari's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bari) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Mountain Lakes
Browse hematologists in Mountain Lakes ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in NJ
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in NJ
Which NJ hematologists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology